The importance of survivorship issues in prostate cancer

Saturday, 12 March
08:30 - 10:00

Location: Room Vienna (Hall B2, level 0)
Chairs: K. Mastris, Clayhall Ilford (GB)
G. Morgia, San Giovanni La Punta (IT)
M. Plata, Bogota (CO)

Aims and objectives of this presentation
New therapeutic strategies have produced a clear shift toward extended survival of patients with prostate cancer. Interestingly, the long-term consequences of treatments are still poorly understood in the general community. Understanding these better is the topic of this Survivorship session.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (+) are 3 minutes in length, followed by 3 minutes for discussion.

*59
Second primary tumors in prostate cancer: Data from two phase III trials
Institutes: 1Centre Hospitalier Universitaire De Sherbrooke, Dept. of Radio-Oncology, Sherbrooke, Canada, 2Centre Hospitalier Universitaire De Sherbrooke, Statistician, M.S.c., Sherbrooke, Canada, 3Centre Hospitalier Universitaire De Québec, Dept. of Radiation Oncology, Québec, Canada, 4Centre Hospitalier Universitaire De Montréal, Dept. of Radiation Oncology, Montréal, Canada, 5Centre Universitaire De Santé McGill, Dept. of Radiation Oncology, Montréal, Canada, 6Hopital Maisonneuve-Rosemont, Dept. of Radiation Oncology, Montréal, Canada, 7Centre De Santé Et Services Sociaux De Chicoutimi, Dept. of Radiation Oncology, Chicoutimi, Canada, 8Centre De Santé Et Services Sociaux De Chicoutimi, Dept. of Radiation Oncology, Chicoutimi, Canada, 9Hopital Général Juif De Montréal, Dept. of Radiation Oncology, Montréal, Canada, 10Hopital De Gatineau, Dept. of Radiation Oncology, Gatineau, Canada, 11Centre Hospitalier Régional De Trois-Rivières, Dept. of Radiation Oncology, Trois-Rivières, Canada

*60
Secondary bladder cancer after anticancer therapy for prostate cancer; reduced comorbidity after androgen-deprivation therapy and increased comorbidity with smoking history
By: Shiota M.1, Yokomizo A.1, Takeuchi A.1, Imada K.1, Kiyoshima K.1, Inokuchi J.1, Tatsugami K.1, Ohga S.2, Nakamura K.2, Honda H.2, Naito S.1, Eto M.1
Institutes: 1Kyushu University, Dept. of Urology, Fukuoka, Japan, 2Kyushu University, Dept. of Clinical Radiology, Fukuoka, Japan

*61
Prophylactic irradiation of pelvic lymph-nodal area after prostatectomy does not increase the risk of second neoplasms: A single institution analysis of 1109 patients with 10 years follow-up
By: Sini C.2, Cozzarini C.2, Fiorino C.2, Briganti A.2, Deantoni C.2, Fodor A.2, Fossati N.2, Gandaglia G.2, Noris Chioria B.2, Perna L.2, Montorsi F.2, Calandrino R.2, Di Muzio N.1
Institutes: 1San Raffaele Scientific Institute, Dept. of Radiotherapy, Milan, Italy, 2San Raffaele Scientific Institute, Dept. of Medical Physics, Milan, Italy, 3San Raffaele Scientific Institute, Dept. of Urology, Milan, Italy

*62
What is the color of cancer?
By: Tatli V., Ucer O., Muezzinoglu T.
Institutes: Celal Bayar University Faculty of Medicine, Dept. of Urology, Manisa, Turkey
**Poster Session 06**

**#63**

**Online support groups offer low-threshold backing for caregivers of patients with prostate cancer**

By: Renner T.¹, Maatz P.¹, Muck T.¹, Ihrig A.², Huber J.¹

**Institutes:** Medical Faculty Carl Gustav Carus, Tu Dresden, Dept. of Urology, Dresden, Germany, ²University of Heidelberg, Dept. of General Internal Medicine and Psychosomatic, Heidelberg, Germany

**#64**

**When should patients undergo prostate biopsy? Decision analysis using differences in the health-related quality-of-life between pre-biopsy healthy men and patients with castration-resistant prostate cancer**

By: Ishioka J.¹, Masuda H.², Inoue M.¹, Itoh M.¹, Yoshida S.¹, Yokoyama M.¹, Matsuoka Y.¹, Numao N.¹, Saito K.¹, Fujiy Y.¹, Kihara K.¹

**Institutes:** Tokyo Medical and Dental University Graduate School, Dept. of Urology, Tokyo, Japan, ²The Cancer Institute Hospital, Japanese Foundation For Cancer Research, Dept. of Urology, Tokyo, Japan

**#65**

**Effect of prostate specific antigen parameters on global quality of life in prostate cancer patients during follow-up**

By: Kao Y-L.¹, Tsai Y-S.¹, Ou F-Y.¹, Lin Z-Y.², Ou C-H.¹, Yang W-H.¹, Chen H-L.¹, Tzai T-S.¹, Wang J-D.²

**Institutes:** ¹National Cheng Kung University Hospital, Dept. of Urology, Tainan, Taiwan, ²National Cheng Kung University, Dept. of Public Health, Tainan, Taiwan

**#66**

**The correlation between retrograde leak point pressure and 24-hour pad weight for men with post prostatectomy incontinence**

By: Solomon E., Malde S., Pakzad M., Hamid R., Shah J., Greenwell T.J., Ockrim J.

**Institutes:** University College London Hospitals, Dept. of Urology, London, United Kingdom

**#67**

**The impact of subsequent metastases on survival and medical costs in prostate cancer patients**

By: Li T.¹, Shore N.D.², Mehra M.³, Todd M.⁴, Saadi R.¹, Leblay G.⁵, Griffiths R.⁶

**Institutes:** ¹Janssen Global Services, Health Economics and Global Market Access, Raritan, United States of America, ²Carolina Urologic Research Center, Atlantic Urology Clinics, Myrtle Beach, United States of America, ³Janssen Global Services, Market Access Analytics and Policy, Raritan, United States of America, ⁴Janssen Global Services, Medical Affairs, Raritan, United States of America, ⁵Janssen Global Services, Global Oncology Strategy, Raritan, United States of America, ⁶Boston Health Economics, Health Services Consulting, Waltham, United States of America

**#68**

**Initial experience of an algorithm-based protocol for the community follow-up of men with stable prostate cancer**

By: Goodall P.¹, Little J.¹, Robinson E.¹, Trimble I.², Cole O.³, Walton T.¹

**Institutes:** Nottingham City Hospital, Dept. of Urology, Nottingham, United Kingdom, ²Nottingham City Clinical Commissioning Group, Dept. of Clinical Commissioning, Nottingham, United Kingdom, ³Medical Specialist Group, Dept. of Urology, Guernsey, United Kingdom

**#69**

**Prospective evaluation of erectile function during four years after brachytherapy in men with low risk prostate cancer and baseline IIEF5 > 16**

By: Schoentgen N.¹, Delage F.¹, Perrouin-Verbe M-A.¹, Coquet J-B.¹, Malhaire J-P.², Fournier G.¹, Valeri A.¹

**Institutes:** Brest University Hospital, Dept. of Urology, Brest, France, ²Brest University Hospital, Dept. of Radiotherapy, Brest, France

**#70**

**Osteoporosis among men with prostate cancer during treatment with androgen deprivation therapy**

By: Poulsen M.H.¹, Frost M.², Abrahamsen B.³, Gerke O.⁴, Walter S.¹

**Institutes:** Odense University Hospital, Dept. of Urology, Odense C, Denmark, ²Odense University Hospital, Dept. of Endocrinology and Metabolism, Odense C, Denmark, ³Holbaek Hospital, Dept. of Medicine and Endocrinology, Holbaek, Denmark, ⁴Odense University Hospital, Dept. of Nuclear Medicine, Odense C, Denmark
Morbidity, mortality and costs of treatment for locally advanced prostate cancer: A population-based analysis comparing radical prostatectomy and external beam radiation

By: Meyer C.¹, Feldman A.², Sanchez A.², Reznor G.¹, Hanske J.¹, Hanna N.¹, Kibel A.¹, Sammon J.³, Cole A.¹, Leow J.¹, Sun M.¹, Trinh Q-D.¹

Institutes: ¹Brigham and Women’s Hospital, Division of Urologic Surgery and Center For Surgery and Public Health, Boston, United States of America, ²Massachusetts General Hospital, Dept. of Urology, Boston, United States of America, ³Henry Ford Hospital, Vatikutti Urology Institute, Boston, United States of America